Skip to main contentSkip to navigation
Sirius Investors

BWAY Stock: BrainsWay Ltd. Stock Price, Analysis & Insights

Get live BWAY stock price $14.15, comprehensive BrainsWay Ltd. stock analysis, charts, news, and expert forecast. Real-time BWAY stock data and investment insights.

14.15
1.94%Today
BWAYBrainsWay Ltd. • NASDAQ Global Market • Healthcare
Market Cap
555.01M
Volume
128.84K
52W High
17.35
52W Low
5.33

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among...

Company Information

CEO
Hadar Levy
Sector
Healthcare
Industry
Medical - Devices
Employees
120

Contact Information

Address
Bynet Building
Country
IL

Investment Analysis & Business Insights

Healthcare
Medical - Devices

Investment Highlights

Strong presence in the Healthcare sector with established market position

Growth-oriented company with premium valuation (P/E: 64.3)

Lower volatility stock (Beta: 0.15) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for BrainsWay Ltd. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for BrainsWay Ltd.
  • Investors should consider how BrainsWay Ltd. fits within their overall portfolio allocation
  • Premium valuation (P/E: 64.3) requires strong growth to justify

Market Cap

555.01M

P/E Ratio (TTM)

64.32

Beta

0.15

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.